2023-05-01 12:00:00 ET
- Salarius Pharma ( NASDAQ: SLRX ) completes 2 Good Laboratory Practice toxicology studies on its protein degrader SP-3164, with no unexpected safety findings.
- The company said the GLP toxicology reports will be included in the investigational new drug application and it plans to submit to the U.S. Food and Drug Administration in the second quarter of 2023.
- Salarius had a pre-IND meeting with the FDA in May 2022 and plans to start a P hase 1 study in H2 2023 .
For further details see:
Salarius Pharma targeted protein degrader SP-3164 shows no adverse safety signals in good laboratory practice toxicology studies